Welcome to our dedicated page for Eledon Pharmaceuticals SEC filings (Ticker: ELDN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Eledon Pharmaceuticals, Inc. (ELDN) SEC filings page provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Eledon is a clinical stage biotechnology company focused on immune-modulating therapies built around the CD40 Ligand (CD40L) pathway, with its common stock listed on the Nasdaq Capital Market under the symbol ELDN, as noted in its Form 8-K filings.
Through this page, readers can review key documents such as annual reports on Form 10-K and quarterly reports on Form 10-Q, which describe Eledon’s clinical programs for its lead investigational product tegoprubart, risk factors, and financial position. Current reports on Form 8-K provide more targeted updates, including material events related to clinical data disclosures, financing transactions and other significant corporate developments.
For example, an 8-K dated November 12, 2025 outlines an underwriting agreement for an underwritten public offering of common stock and pre-funded warrants, including the intended use of net proceeds to support continued clinical development and pipeline advancement. Other 8-K filings describe preliminary cash, cash equivalents and short-term investment balances, as well as press releases announcing Phase 2 BESTOW trial results and updated data from a Phase 1b kidney transplant study.
On Stock Titan, these filings are supplemented by AI-powered summaries that explain the main points of lengthy documents, helping users quickly understand topics such as capital raises, clinical trial disclosures and selected financial information. Real-time updates from EDGAR allow timely viewing of new ELDN filings, while access to forms like 10-K, 10-Q and 8-K supports deeper analysis of Eledon’s clinical-stage operations, financing activities and risk disclosures.
Date: August 6, 2025.
Eledon Pharmaceuticals, Inc. (ELDN) disclosed updated data from its ongoing Phase 1b open-label trial of tegoprubart for the prevention of organ rejection in kidney transplant patients. The results were presented at the World Transplant Congress in San Francisco, CA. The company issued a press release (attached as Exhibit 99.1) and hosted a conference call on the same date. The presentation for the call will be posted on the company investor site at https://ir.eledon.com/investor-relations prior to the call.
The filing notes that the Item 7.01 disclosure and Exhibit 99.1 are not deemed "filed" under Section 18 of the Exchange Act and are not incorporated by reference into Securities Act or Exchange Act filings unless expressly stated.